ANNEX A
Representatives nominated by Estonia
Mandate Nomination
Name Membership
Expiry Date Due Date
Committee on Orphan Medicinal Products (COMP) Vallo Tillmann Member 17 May 2021 17 March 2021
Mandates will be presumed to take effect the day following expiry of the current mandate unless otherwise indicated.
Nominations for CHMP and CVMP representatives are subject to appropriate consultation of the European Medicines Agency's Management Board
in accordance with Article 61 of Regulation (EC) no. 726/2004.
# Classified as confidential by the European Medicines Agency Page 2 of 2
Saatja: Obon Roger <
[email protected]>
Saaja: Esindus EL juures üldaadress, Nominations
Teema: Estonia - 2021-01-13 - Nomination invitation for COMP member
For the attention of HE Mr Aivo Orav,
Your Excellency,
Please find attached a letter from the Executive Director of the European Medicines Agency regarding the nomination of representatives in the Committee for Orphan Medicinal Products (COMP).
Kind regards,
Roger Obon
Experts and Declarations of Interests Management
Meeting Secretariat Office
Committees and Quality Assurance Department
European Medicines Agency
Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands
Telephone +31 (0)88 781 6763
[email protected]<mailto:
[email protected]> | www.ema.europa.eu<https://www.ema.europa.eu/en> | For directions, see How to find us<https://www.ema.europa.eu/en/about-us/contact/how-find-us>
Follow us: [cid:
[email protected]] [cid:
[email protected]] [cid:
[email protected]]
This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.
P Please consider the environment before printing this e-mail
Classified as confidential by the European Medicines Agency
________________________________________________________________________
This e-mail has been scanned for all known viruses by European Medicines Agency.
________________________________________________________________________
HE Mr Aivo Orav
Permanent Representation of Estonia
to the European Union
Rue Guimard 11-13
B-1040 Brussels
BELGIUM
13 January 2021
EMA/19244/2021
Executive Director
Your Excellency,
Subject: Nomination of representatives in the Committee for Orphan Medicinal Products
(COMP)
The European Medicines Agency was established by Regulation (EC) No 726/2004. Members and
alternates of the Agency’s Management Board and scientific committees are nominated for a three-
year mandate by EU member states and EEA-EFTA countries.
The three-year mandate of the representative listed in Annex A is due to expire. I, therefore, invite
you to nominate representative for a new three-year mandate starting 18/05/2021. In case you are
nominating new representative and a different start date for the mandate is envisaged, please inform
me accordingly.
If no nomination for representatives is received by the end date of the current mandate, the positions
will be considered vacant for a three-year period or until a nomination is received.
In making your nominations, please note that the Agency’s Management Board has determined that
members of scientific committees should meet conditions concerning their declarations of interests as
described in the Policy on the handling of competing interests of scientific committees’ members and
experts. This policy can be found on the EMA website.
I would like to draw your attention to the attached Annex B, which lists the recommended criteria for
experience and expertise of COMP members and alternates for consideration when nominating a new
representative.
As agreed with the network of the Heads of Medicines Agencies in order to address the increasing
complexity in scientific developments related to the committee’s activities, the current expertise of the
committee and the expertise required for upcoming procedures are monitored. It would be appreciated
if the following specific areas of expertise that were identified as desirable for the current and
upcoming work of the committee, could be taken into consideration when nominating a new
representative, subject to the availability of such expertise to the relevant competent authority in your
country:
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.
• Statistics (medical statistician)
• Clinical specialist in:
− Skin disorders (dermatologist)
− Infectious diseases
• Genetics
An overview of the current composition of the Committee and the expertise of its members is attached
for your information.
Please address the nominations to my attention at PO Box 71010, 1008 BA Amsterdam, The
Netherlands, indicating full contact details for the nominees and the start date of the mandate,
together with any additional information you believe may assist these nominations. In case you have
already posted me your nominations, I kindly ask you to disregard this correspondence.
A copy of this letter will be forwarded to the head of the relevant competent authority in your country.
Yours faithfully,
Emer Cooke Digitally signed by Emer Cooke
Date: 2021.01.15 20:10:14 +01'00'
Emer Cooke
Executive Director
Encs:
Annex A
Annex B
Current COMP composition and expertise
EMA/19244/2021 Page 2/2
Saatja: Webdesktop <
[email protected]>
Saadetud: 18.01.2021 18:35
Adressaat: SM Info <
[email protected]>; info ravimiamet ee <
[email protected]>;
<
[email protected]>; Elen Ohov <
[email protected]>
Koopia: <
[email protected]>
Teema: Webdesktop: Kiri nr 14-4/56 / Esindaja nimetamine Euroopa
Ravimiameti harvikravimite komiteesse (COMP)
Tere!Edastan Euroopa Ravimiameti kirja. Palun andke enne 17.03.2021 EV
AEEL-le teada (
[email protected], cc:
[email protected]), kas me
pikendame praeguse liikme Vallo Tillmanni mandaati või nimetame uue.Reg.
number: 14-4/56Reg. kuupäev: 18.01.2021Sisu: Letter from the Executive
Director of the European Medicines Agency regarding the nomination of
representatives in the Committee for Orphan Medicinal Products
(COMP).Heade soovidegaTiiu
[email protected]är EV AEEL
juures*** TÄHELEPANU *** See e-kiri (kaasa arvatud manused) on mõeldud
ainult e-kirja adressaatidele ning võib sisaldada ametialaseks
kasutamiseks ettenähtud teavet. Teavet ei tohi ilma saatja selgelt
väljendatud loata edasi saata ega mistahes viisil kõrvaliletse isikutele
avaldadauJ .hul, kui Te olete saanud käesoleva e-kirja eksituse tõttu,
palun teavitage sellest kohe saatjat ning kustutage e-kiri oma
arvutist.*** ATTENTION *** This e-mail and its attachments may contain
official information. If you are not the intended recipient, please
notify the sender immediately, delete this e-mail and destroy any copies.
Any dissemination or use of this information by a person other than the
intended recipient is unauthorized and may be unlawful.